PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
London (PRWEB) October 24, 2013 -- PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, “PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
As in the other markets covered in this report, the patent expirations of the key marketed drugs will drive a reduction in the market until 2015; both Aricept and Reminyl lost market exclusivity in 2012, and Ebixa will come off patent in 2014. Arimenda, the FDC reformulation of two of the expiring medications, is expected to enter the market in the short term, but is not expected to make up for the sales lost by the patent cliff for Aricept and Ebixa.
Scope
-Overview of Alzheimer’s Disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in the UK from 2012-2022.
-Analysis of the impact of key events as well the drivers and restraints affecting the UK Alzheimer’s Disease market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for Alzheimer’s Disease
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2012-2022 in the UK
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Disease Overview 14
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 18
3.2 Symptoms 30
4 Disease Management 32
4.1 Diagnosis 32
4.1.1 Probable Alzheimer’s Disease Dementia 33
4.1.2 Possible AD Dementia 34
4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 34
4.1.4 Possible Alzheimer’s Dementia with Evidence of the Alzheimer’s Disease Pathophysiological Process 35
4.1.5 Preclinical AD 35
4.1.6 Mild Cognitive Impairment 36
4.2 Treatment Overview 38
4.3 UK 41
4.3.1 Diagnosis 41
4.3.2 Clinical Practice 41
5 Competitive Assessment 43
5.1 Overview 43
5.2 Strategic Competitor Assessment 43
5.3 Product Profiles - Major Brands 46
5.3.1 Aricept (donepezil hydrochloride) 46
5.3.2 Exelon (rivastigmine, rivastigmine tartrate) 50
5.3.3 Razadyne (galantamine hydrobromide) 55
5.3.4 Namenda (memantine hydrochloride) 59
6 Opportunity and Unmet Need 63
6.1 Unmet Needs Overview 63
6.1.1 Public Awareness 65
6.1.2 Specialized Institutions at Local Levels 66
6.1.3 Screening and Diagnosis 66
6.1.4 Early Intervention 67
6.1.5 Improved Clinical Trial Design 68
6.1.6 Effective Therapy 69
6.1.7 Behavioral Treatments 70
6.2 Gap Analysis 70
6.2.1 Disease Prevention 71
6.2.2 Diagnosis from Biomarkers 72
6.2.3 Behavioral Therapies 73
7 Pipeline Assessment 74
7.1 Overview 74
7.2 Early-Stage Pipeline Assessment 74
7.3 AD Pipeline by Mechanism of Action 76
7.4 Enzymatic Processing 77
7.5 Immunization 78
7.6 Anti-Aggregation 78
7.7 “Me-Too” 79
7.8 Novel Therapeutic Approaches 80
7.9 Technology Trends Analytic Framework 80
7.10 Promising Drugs in Clinical Development 81
7.10.1 Arimenda 83
7.10.2 Solanezumab 86
7.10.3 Gantenerumab 90
7.10.4 Crenezumab 94
7.10.5 TRx0237 98
7.10.6 MK-8931 101
7.10.7 EVP-6124 104
7.10.8 Lu AE58054 107
8 Market Outlook 111
8.1 United Kingdom 111
8.1.1 Forecast 111
8.1.2 Key Events 114
8.1.3 Drivers and Barriers 114
9 Appendix 118
9.1 Bibliography 118
9.2 Abbreviations 129
9.3 Methodology 135
9.4 Forecasting Methodology 135
9.4.1 Diagnosed AD patients 135
9.4.2 Percent Drug-treated Patients 136
9.4.3 Drugs Included in Each Therapeutic Class 136
9.4.4 Launch and Patent Expiry Dates 137
9.4.5 General Pricing Assumptions 138
9.4.6 Individual Drug Assumptions 139
9.4.7 Generic Erosion 144
9.4.8 Pricing of Pipeline Agents 144
9.5 Physicians and Specialists Included in this Study 145
9.6 About the Authors 146
9.6.1 Author 146
9.6.2 Global Head of Healthcare 147
9.7 About GlobalData 148
9.8 Disclaimer 148
List of Tables
Table 1:Symptoms of AD 31
Table 2:Guidelines for the Treatment of AD 38
Table 3:Most Prescribed Drugs for AD by Class in the Global Markets, 2012 39
Table 4:Leading Branded Treatments for AD, 2013 44
Table 5:Product Profile - Aricept 47
Table 6:Aricept SWOT Analysis, 2013 50
Table 7:Product Profile- Exelon 51
Table 8:Exelon SWOT Analysis, 2012 54
Table 9:Product Profile - Razadyne 56
Table 10:Razadyne SWOT Analysis, 2013 58
Table 11:Product Profile- Namenda 60
Table 12:Namenda SWOT Analysis, 2013 62
Table 13:Overall Unmet Needs - Current Level of Attainment 64
Table 14:Clinical Unmet Needs - Gap Analysis, 2013 71
Table 15:Technology Trends Analytic Framework for the AD Pipeline, 2012 81
Table 16:Comparison of Therapeutic Classes in Development for AD, 2013 81
Table 17:Comparison of Therapeutic Classes in Development for AD, 2013 82
Table 18:Product Profile - Arimenda 83
Table 19:Arimenda SWOT Analysis, 2013 85
Table 20:Product Profile - Solanezumab 86
Table 21:Solanezumab SWOT Analysis, 2013 89
Table 22:Product Profile - Gantenerumab 90
Table 23:Gantenerumab SWOT Analysis, 2013 94
Table 24:Product Profile - Crenezumab 95
Table 25:Crenezumab SWOT Analysis, 2013 97
Table 26:Product Profile - TRx0237 98
Table 27:TRx0237 SWOT Analysis, 2013 100
Table 28:Product Profile - MK-8931 101
Table 29:MK-8931 SWOT Analysis, 2013 104
Table 30:Product Profile - EVP-6124 105
Table 31:EVP-6124 SWOT Analysis, 2013 107
Table 32:Product Profile - Lu AE58054 108
Table 33:Lu AE58054 SWOT Analysis, 2013 110
Table 34:Sales Forecasts ($m) for AD in the United Kingdom, 2012-2022 112
Table 35:Key Events Impacting Sales for AD in the United Kingdom, 2012-2022 114
Table 36:AD Market in the United Kingdom - Drivers and Barriers, 2012-2022 114
Table 37:Key Launch Dates 137
Table 38:Key Patent Expirations 138
List of Figures
Figure 1:Atrophy of the Brain in AD 20
Figure 2:Key Pathological Features in AD Versus a Healthy Neuron 22
Figure 3:Non-Amyloidogenic Metabolism of APP 24
Figure 4:Amyloidogenic Metabolism of APP 25
Figure 5:Neurofibrillary Tangles 27
Figure 6:Oxidative Damage Due to Free Radicals 29
Figure 7:Strategic Competitor Assessment of the Marketed Products in AD, 2013 45
Figure 8:AD - Pipeline Drugs by Target, 2012 75
Figure 9:Competitive Assessment of Late-Stage Pipeline Agents in AD, 2012-2022 82
Figure 10:Sales for AD in the United Kingdom by Drug Class, 2012-2022 113
Read the full report:
PharmaPoint: Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article